See more : AV Promotions Holdings Limited (8419.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Cogent Biosciences, Inc. (COGT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cogent Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Onconova Therapeutics, Inc. (ONTX) Income Statement Analysis – Financial Results
- Foods & Inns Ltd (FOODSIN.NS) Income Statement Analysis – Financial Results
- Tiger Brands Limited (TBS.JO) Income Statement Analysis – Financial Results
- Silo Wellness Inc. (SILFF) Income Statement Analysis – Financial Results
- Medios AG (0QB4.L) Income Statement Analysis – Financial Results
Cogent Biosciences, Inc. (COGT)
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 7.87M | 22.50M | 9.73M | 8.36M | 6.36M | 2.99M |
| Cost of Revenue | 3.59M | 5.88M | 147.00K | 25.74K | 43.71K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.59M | -5.88M | -147.00K | 7.85M | 22.46M | 9.73M | 8.36M | 6.36M | 2.99M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 99.67% | 99.81% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 170.17M | 121.63M | 55.91M | 72.65M | 43.71M | 38.29M | 29.83M | 21.99M | 6.85M |
| General & Administrative | 34.38M | 26.21M | 19.64M | 17.42M | 10.97M | 7.45M | 4.68M | 3.43M | 2.73M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.38M | 26.21M | 19.64M | 17.42M | 10.97M | 7.45M | 4.68M | 3.43M | 2.73M |
| Other Expenses | 0.00 | 3.61M | 2.81M | -246.00K | 78.00K | 320.00K | 274.00K | 681.00K | 0.00 |
| Operating Expenses | 208.13M | 147.84M | 75.55M | 90.07M | 54.68M | 45.74M | 34.51M | 25.43M | 9.58M |
| Cost & Expenses | 208.13M | 147.84M | 75.55M | 90.07M | 54.68M | 45.74M | 34.51M | 25.43M | 9.58M |
| Interest Income | 13.08M | 3.99M | 467.00K | 144.00K | 267.00K | 1.15M | 386.00K | 265.00K | 0.00 |
| Interest Expense | 0.00 | 3.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.27M | 5.88M | 147.00K | 720.00K | 1.29M | 1.32M | 1.17M | 830.00K | 179.00K |
| EBITDA | -205.86M | -134.36M | -75.40M | -34.57M | -30.89M | -34.68M | -24.98M | -18.24M | -6.41M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1,139.52% | -143.02% | -356.32% | -298.82% | -287.02% | -214.77% |
| Operating Income | -208.13M | -147.84M | -75.55M | -82.20M | -32.18M | -36.01M | -26.15M | -19.07M | -6.59M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1,044.33% | -143.02% | -369.89% | -312.82% | -300.08% | -220.76% |
| Total Other Income/Expenses | 15.72M | 7.60M | 3.28M | 7.39M | 345.00K | 1.47M | 660.00K | 946.00K | 0.00 |
| Income Before Tax | -192.41M | -140.24M | -72.27M | -74.81M | -31.83M | -34.53M | -25.49M | -18.12M | -6.59M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -950.43% | -141.49% | -354.76% | -304.93% | -285.19% | -220.76% |
| Income Tax Expense | 0.00 | -7.60M | -467.00K | -8.36M | -1.56M | 1.47M | -386.00K | -265.00K | 0.00 |
| Net Income | -192.41M | -132.64M | -71.81M | -66.45M | -30.27M | -34.53M | -25.49M | -18.12M | -6.59M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -844.25% | -134.55% | -354.76% | -304.93% | -285.19% | -220.76% |
| EPS | -2.42 | -2.26 | -1.85 | -6.00 | -3.97 | -5.55 | -3.45 | -3.10 | -1.13 |
| EPS Diluted | -2.42 | -2.26 | -1.85 | -6.00 | -3.97 | -5.55 | -3.45 | -2.45 | -0.89 |
| Weighted Avg Shares Out | 79.66M | 58.74M | 38.73M | 11.08M | 7.62M | 6.22M | 7.40M | 5.86M | 5.86M |
| Weighted Avg Shares Out (Dil) | 79.66M | 58.74M | 38.73M | 11.08M | 7.62M | 6.22M | 7.40M | 7.40M | 7.40M |
Cogent Biosciences Provides 2022 Corporate Guidance
Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
Cogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 Financial Results
Cogent Biosciences to Present Preclinical Data on Bezuclastinib at AACR-NCI-EORTC Conference
Cogent Biosciences Provides Corporate Updates and Reports Second Quarter 2021 Financial Results
Cogent Biosciences to Present at Ladenburg Thalmann Virtual Healthcare Conference 2021
Cogent Biosciences to Present at Jefferies Virtual Healthcare Conference 2021
Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results
Cogent Biosciences Appoints Evan Kearns as Chief Legal Officer
Source: https://incomestatements.info
Category: Stock Reports